pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ProMIS Neurosciences Inc. ($PMN) · news · pharmadog
← back to ProMIS Neurosciences Inc.
News mentioning $PMN
13
stories
14h
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
stat
2d
STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
stat
7d
STAT+: What to know about Biogen’s big lupus study readout
stat
7d
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
stat
14d
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
stat
14d
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
stat
14d
STAT+: A possible comeback for a failed sickle cell gene therapy
stat
14d
STAT+: Beyond statins, one drug lowered heart attack risk by 20%
stat
14d
STAT+: Medicare delays controversial remote patient monitoring rule to 2029
stat
14d
STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
stat
14d
STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
stat
Oct 8, 26
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
Jul 28, 26
STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment
stat